scholarly article | Q13442814 |
P356 | DOI | 10.1093/JNCI/DJW290 |
P698 | PubMed publication ID | 28130475 |
P50 | author | Yiwey Shieh | Q81345889 |
Laura Esserman | Q91960202 | ||
P2093 | author name string | Elad Ziv | |
Jeffrey A Tice | |||
Lisa Madlensky | |||
Laura J Van't Veer | |||
Martin Eklund | |||
Allison Stover Fiscalini | |||
Carlie K Thompson | |||
Sarah D Sawyer | |||
Athena Breast Health Network Investigators | |||
P2860 | cites work | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 |
Screening for breast cancer: an update for the U.S. Preventive Services Task Force | Q24615837 | ||
Gene-environment interaction and risk of breast cancer | Q26772236 | ||
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society | Q27347760 | ||
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations | Q28215462 | ||
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography | Q28295438 | ||
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk | Q28390064 | ||
Presymptomatic risk assessment for chronic non-communicable diseases | Q28743818 | ||
Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
Population-based screening for cancer: hope and hype. | Q30251601 | ||
A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. | Q37284382 | ||
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies | Q37364628 | ||
Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model | Q37378034 | ||
ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma | Q37764404 | ||
A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance | Q37950847 | ||
Benefits and Harms of Breast Cancer Screening: A Systematic Review | Q38616415 | ||
Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation | Q38693248 | ||
Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation | Q38693328 | ||
CDH1 germline mutations and hereditary lobular breast cancer. | Q38694163 | ||
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers | Q39437211 | ||
Mammography Use and Physician Recommendation After the 2009 U.S. Preventive Services Task Force Breast Cancer Screening Recommendations | Q40176894 | ||
Breast cancer risk prediction using a clinical risk model and polygenic risk score | Q40605693 | ||
Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program | Q44609406 | ||
Risk factors for breast cancer according to estrogen and progesterone receptor status | Q44753983 | ||
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma | Q45854491 | ||
Personalized Screening for Breast Cancer: A Wolf in Sheep's Clothing? | Q46114265 | ||
Predicting risk of breast cancer in postmenopausal women by hormone receptor status | Q46901894 | ||
Validation studies for models projecting the risk of invasive and total breast cancer incidence. | Q50651945 | ||
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. | Q50748795 | ||
Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. | Q51933968 | ||
A breast cancer prediction model incorporating familial and personal risk factors. | Q52000310 | ||
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. | Q52274948 | ||
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement | Q54092157 | ||
ACR Appropriateness Criteria Breast Cancer Screening | Q57132506 | ||
Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. | Q30620197 | ||
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention | Q32133889 | ||
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition | Q33205307 | ||
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer | Q33549627 | ||
TP53 mutations in human cancers: origins, consequences, and clinical use | Q33685392 | ||
Breast cancer after chest radiation therapy for childhood cancer | Q33910979 | ||
Counselling framework for moderate-penetrance cancer-susceptibility mutations | Q33911135 | ||
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia | Q34049245 | ||
A comprehensive examination of breast cancer risk loci in African American women | Q34211808 | ||
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information | Q34267477 | ||
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. | Q34314370 | ||
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force | Q34339445 | ||
Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. | Q34375940 | ||
Cancer risks and mortality in heterozygous ATM mutation carriers | Q34422846 | ||
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement | Q34508652 | ||
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome | Q34567595 | ||
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening | Q34977428 | ||
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium | Q35166701 | ||
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme | Q35441054 | ||
Lifetime cancer risks in individuals with germline PTEN mutations. | Q35681689 | ||
Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled | Q35869663 | ||
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer | Q36090967 | ||
The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
Gene-panel sequencing and the prediction of breast-cancer risk | Q36175072 | ||
Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines | Q36426749 | ||
Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry | Q36619329 | ||
Genetic susceptibility to triple-negative breast cancer | Q36846498 | ||
Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls | Q36856357 | ||
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy | Q36976948 | ||
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness | Q37139381 | ||
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model | Q37172219 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | breast cancer screening | Q17011492 |
P577 | publication date | 2017-01-27 | |
P1433 | published in | Journal of the National Cancer Institute | Q400279 |
P1476 | title | Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial | |
P478 | volume | 109 |
Q64115284 | 10-year performance of four models of breast cancer risk: a validation study |
Q92654615 | Age-based versus Risk-based Mammography Screening in Women 40-49 Years Old: A Cross-sectional Study |
Q88660564 | Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools |
Q61443339 | Cancer prevention and screening: the next step in the era of precision medicine |
Q89746441 | Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field |
Q47703662 | Common Genetic Variation and Breast Cancer Risk - Past, present, and future |
Q90213124 | Community education to enhance the more equitable use of precision medicine in Northern Manhattan |
Q92528444 | Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification |
Q47298550 | Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants |
Q38371172 | E-Science technologies in a workflow for personalized medicine using cancer screening as a case study |
Q89799256 | Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives |
Q64080586 | Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer |
Q90690238 | Interval breast cancer risk associations with breast density, family history and breast tissue aging |
Q64123868 | Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families |
Q39270600 | Managing hereditary breast cancer risk in women with and without ovarian cancer |
Q47932976 | Optical assessment of mammographic breast density by a 12-wavelength vs a continuous-spectrum optical spectroscopy device |
Q103027570 | Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction |
Q93060888 | Paradigm Shift From Halstedian Radical Mastectomy to Personalized Medicine |
Q57453316 | Personalised medicine and population health: breast and ovarian cancer |
Q54965951 | Personalized cancer screening: helping primary care rise to the challenge. |
Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
Q55010484 | Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment. |
Q52648008 | Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. |
Q91458164 | Precision risk-based screening might maximize benefit and minimize harm |
Q92152748 | Response to Peshkin, Isaacs, and Schwartz |
Q54950358 | Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. |
Q47130981 | The Complexity of Achieving the Promise of Precision Breast Cancer Screening. |
Q92282029 | The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches |
Q41701590 | The WISDOM Study: breaking the deadlock in the breast cancer screening debate |
Q64240122 | Towards a more precise and individualized assessment of breast cancer risk |
Q59335358 | Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer |
Q90665404 | We need more evidence to answer questions about screening |
Q60927268 | What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries |
Search more.